Eli Lilly scores expanded MACE label for Trulicity; Gilead's CAR-T Yescarta gets in China review line
→ The FDA has expanded the label for Eli Lilly‘s type 2 diabetes drug Trulicity, saying that it is now approved to lower the risk of a major adverse cardiac event. The expanded approval comes after a nearly decade-long trial of nearly 10,000 patients on Trulicity or placebo showed that the drug slightly lowered the risk of cardiovascular death, nonfatal heart attack and nonfatal stroke. Trulicty is a GLP-1 agonist, meaning it increases insulin secretion and reduces glucagon secretion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.